ID   Lu-139
AC   CVCL_1390
SY   NCC-c-Lu-139; LU-139; Lu139; LU139
DR   CLO; CLO_0037023
DR   CLO; CLO_0050031
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472318
DR   cancercelllines; CVCL_1390
DR   Cell_Model_Passport; SIDM00293
DR   CGH-DB; 93-1
DR   CGH-DB; 9063-4
DR   ChEMBL-Cells; CHEMBL3308238
DR   ChEMBL-Targets; CHEMBL2366248
DR   Cosmic; 713878
DR   Cosmic; 801607
DR   Cosmic; 809123
DR   Cosmic; 844822
DR   Cosmic; 876156
DR   Cosmic; 918007
DR   Cosmic; 929158
DR   Cosmic; 1212195
DR   Cosmic; 1239931
DR   Cosmic; 1571751
DR   Cosmic; 1995495
DR   Cosmic; 2125268
DR   Cosmic; 2668340
DR   Cosmic-CLP; 713878
DR   DepMap; ACH-002052
DR   EGA; EGAS00001000978
DR   GDSC; 713878
DR   GEO; GSM1670065
DR   IARC_TP53; 1017
DR   LINCS_LDP; LCL-1872
DR   PharmacoDB; LU139_867_2019
DR   PRIDE; PXD011896
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1390
DR   RCB; RCB0469
DR   Wikidata; Q54903195
RX   PubMed=1312700;
RX   PubMed=1847845;
RX   PubMed=3022030;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=12107105;
RX   PubMed=15901131;
RX   PubMed=19472407;
RX   PubMed=20164919;
RX   PubMed=20557307;
RX   PubMed=23716474;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 29 hours (PubMed=3022030).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175; PubMed=15901131; PubMed=20557307).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.34%; Native American=0%; East Asian, North=86.97%; East Asian, South=5.88%; South Asian=2.89%; European, North=2.93%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 9
ST   D5S818: 13
ST   D7S820: 12
ST   TH01: 9
ST   TPOX: 8,12
ST   vWA: 17
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   PubMed=1312700;
RA   Sameshima Y., Matsuno Y., Hirohashi S., Shimosato Y., Mizoguchi H.,
RA   Sugimura T., Terada M., Yokota J.;
RT   "Alterations of the p53 gene are common and critical events for the
RT   maintenance of malignant phenotypes in small-cell lung carcinoma.";
RL   Oncogene 7:451-457(1992).
//
RX   PubMed=1847845; DOI=10.1007/BF00685110;
RA   Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T.,
RA   Saijo N.;
RT   "Prediction of the antitumor activity of new platinum analogs based on
RT   their ex vivo pharmacodynamics as determined by bioassay.";
RL   Cancer Chemother. Pharmacol. 27:263-270(1991).
//
RX   PubMed=3022030; DOI=10.1093/oxfordjournals.jjco.a039144;
RA   Terasaki T., Shimosato Y., Nakajima T., Tsumuraya M., Morinaga S.,
RA   Hirohashi S., Yamaguchi K., Kato K., Ichinose H., Nagatsu T.;
RT   "Changes in cell characteristics due to culture conditions in cell
RT   lines from human small cell lung cancer.";
RL   Jpn. J. Clin. Oncol. 16:203-212(1986).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=12107105; DOI=10.1016/S0002-9440(10)64172-7;
RA   Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T.,
RA   Fujisawa T., Terasaki T., Horii A., Takahashi T., Hirohashi S.,
RA   Inazawa J.;
RT   "A novel target gene, SKP2, within the 5p13 amplicon that is
RT   frequently detected in small cell lung cancers.";
RL   Am. J. Pathol. 161:207-216(2002).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=23716474; DOI=10.1002/gcc.22076;
RA   Iwakawa R., Takenaka M., Kohno T., Shimada Y., Totoki Y., Shibata T.,
RA   Tsuta K., Nishikawa R., Noguchi M., Sato-Otsubo A., Ogawa S.,
RA   Yokota J.;
RT   "Genome-wide identification of genes with amplification and/or fusion
RT   in small cell lung cancer.";
RL   Genes Chromosomes Cancer 52:802-816(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//